Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
Lung cancer is the leading cause of cancer related deaths. Among the two broad types of
lung cancer, non-small cell lung cancer accounts for 85% of the cases. The study of the …
lung cancer, non-small cell lung cancer accounts for 85% of the cases. The study of the …
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
D Planchard, RE Sanborn, MV Negrao… - NPJ Precision …, 2024 - nature.com
In this review, we cover the current understanding of BRAF mutations and associated clinical
characteristics in patients with metastatic NSCLC, approved and emerging treatment …
characteristics in patients with metastatic NSCLC, approved and emerging treatment …
[HTML][HTML] Real-world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor-based systemic therapy in BRAF mutation-positive NSCLC
Introduction BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver
and emerging therapeutic target. There is a scarcity of real-world data describing the clinical …
and emerging therapeutic target. There is a scarcity of real-world data describing the clinical …
[HTML][HTML] Minimizing sample failure rates for challenging clinical tumor samples
Identification of somatic variants in cancer by high-throughput sequencing has become
common clinical practice, largely because many of these variants may be predictive …
common clinical practice, largely because many of these variants may be predictive …
[PDF][PDF] Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance
AM Mekhamer, MH Saied, DAE Elneily… - Asian Pacific Journal …, 2024 - journal.waocp.org
Background: Different molecular subtypes, including HER2-positive, have been identified in
breast cancer. The overexpression ofHER2triggers downstream signaling pathways such as …
breast cancer. The overexpression ofHER2triggers downstream signaling pathways such as …
Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience
Aim: We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients
with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 …
with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 …
Real-world analysis of BRAF inhibitors in patients with solid tumors positive for BRAF V600E mutation: A retrospective observational study
Cancer Research, Statistics, and Treatment/Volume 5/Issue 3/July-September 2022 from
India. Our study suggests that the accessibility to BRAF inhibitors among those tested at our …
India. Our study suggests that the accessibility to BRAF inhibitors among those tested at our …
Research progress on the mode and clinical significance of BRAF mutation and co-mutation in non-small cell lung cancer
L LI, J HUANG - xdzlyx.com
Mouse sarcoma virus oncogene homologue B1 (v-raf murine sarcoma viral oncogene
homolog B1, BRAF) gene is one of the important driving genes of non-small cell lung cancer …
homolog B1, BRAF) gene is one of the important driving genes of non-small cell lung cancer …